2.7(top 20%)
impact factor
1.9K(top 10%)
papers
46.0K(top 10%)
citations
81(top 10%)
h-index
2.8(top 20%)
impact factor
2.2K
all documents
47.9K
doc citations
109(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A reviewPulmonary Pharmacology and Therapeutics2007273
2Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airwayPulmonary Pharmacology and Therapeutics2008272
3The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulmonary Pharmacology and Therapeutics2010270
4Reactive Oxygen Species as Mediators in AsthmaPulmonary Pharmacology and Therapeutics2001260
5The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulmonary Pharmacology and Therapeutics2010233
6Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytesPulmonary Pharmacology and Therapeutics2004200
7Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.Pulmonary Pharmacology and Therapeutics2014179
8cAMP regulation of airway smooth muscle functionPulmonary Pharmacology and Therapeutics2013177
9Epidemiology of CoughPulmonary Pharmacology and Therapeutics2002167
10The Non-neuronal Cholinergic System: an Emerging Drug Target in the AirwaysPulmonary Pharmacology and Therapeutics2001162
11Clinical Application of Forced OscillationPulmonary Pharmacology and Therapeutics2001160
12Relationship between neutrophil elastase and acute lung injury in humansPulmonary Pharmacology and Therapeutics2004158
13Resolvin D1 protects mice from LPS-induced acute lung injuryPulmonary Pharmacology and Therapeutics2011157
14ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to ClinicPulmonary Pharmacology and Therapeutics1999156
15Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2–Keap1 signalingPulmonary Pharmacology and Therapeutics2009153
16Glucocorticoid-regulated Transcription FactorsPulmonary Pharmacology and Therapeutics2001149
17Chronic ‘cough hypersensitivity syndrome’: A more precise label for chronic coughPulmonary Pharmacology and Therapeutics2011149
18The Powerful Placebo in Cough Studies?Pulmonary Pharmacology and Therapeutics2002143
19Exploring lung physiology in health and disease with lung slicesPulmonary Pharmacology and Therapeutics2011143
20Molecular Mechanisms of Glucocorticosteroid ActionsPulmonary Pharmacology and Therapeutics2000141
21The inhalers of the future? A review of dry powder devices on the market todayPulmonary Pharmacology and Therapeutics2003136
22Lung cancer in patients with idiopathic pulmonary fibrosisPulmonary Pharmacology and Therapeutics2017129
23Bleomycin lung toxicity: who are the patients with increased risk?Pulmonary Pharmacology and Therapeutics2005128
24Transforming growth factor-β and its role in asthmaPulmonary Pharmacology and Therapeutics2003127
25Markers of disease severity in chronic obstructive pulmonary diseasePulmonary Pharmacology and Therapeutics2006127
26The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulmonary Pharmacology and Therapeutics2004126
27Platinum nanoparticle antioxidants inhibit pulmonary inflammation in mice exposed to cigarette smokePulmonary Pharmacology and Therapeutics2009126
28Review of the Molecular and Cellular Mechanisms of Action of Glucocorticoids for Use in AsthmaPulmonary Pharmacology and Therapeutics2002125
29Calcitonin gene-related peptide as inflammatory mediatorPulmonary Pharmacology and Therapeutics2003125
30The airway cholinergic system: physiology and pharmacologyPulmonary Pharmacology and Therapeutics2004124
31Production of reflex cough by brainstem respiratory networksPulmonary Pharmacology and Therapeutics2004122
32The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot studyPulmonary Pharmacology and Therapeutics2008121
33Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approachPulmonary Pharmacology and Therapeutics2015118
34One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropiumPulmonary Pharmacology and Therapeutics2005112
35Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysisPulmonary Pharmacology and Therapeutics2016112
36Resveratrol alleviates bleomycin-induced lung injury in ratsPulmonary Pharmacology and Therapeutics2007111
37Effect of inhaled corticosteroids on small airways in asthma: Investigation using impulse oscillometryPulmonary Pharmacology and Therapeutics2009111
38Protease-activated Receptor-2 (PAR2) in the AirwaysPulmonary Pharmacology and Therapeutics2001110
39Alternative mechanisms for tiotropiumPulmonary Pharmacology and Therapeutics2009109
40TNF-α inhibitors in asthma and COPD: We must not throw the baby out with the bath waterPulmonary Pharmacology and Therapeutics2010108
41Physiology and Plasticity of Putative Cough Fibres in the Guinea PigPulmonary Pharmacology and Therapeutics2002106
42Onset of Bronchodilation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single InhalersPulmonary Pharmacology and Therapeutics2001105
43Emerging roles for cholesterol and lipoproteins in lung diseasePulmonary Pharmacology and Therapeutics2013105
44Short- and long-term reproducibility of capsaicin cough challenge testingPulmonary Pharmacology and Therapeutics2003104
45Leukotrienes as Mediators of AsthmaPulmonary Pharmacology and Therapeutics2001102
46Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patientsPulmonary Pharmacology and Therapeutics2005102
47Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless designPulmonary Pharmacology and Therapeutics2010102
48Sulfur mustard-induced pulmonary injury: Therapeutic approaches to mitigating toxicityPulmonary Pharmacology and Therapeutics2011102
49Statins, systemic inflammation and risk of death in COPD: The Rotterdam studyPulmonary Pharmacology and Therapeutics2013102
50Complex phenotypes in asthma: Current definitionsPulmonary Pharmacology and Therapeutics2013102